MEASURING DONOR-DERIVED CELL-FREE DNA IN YOUR LABORATORY USING HoloGRAFT

Cell-free DNA (cfDNA) has become the best-studied biomarker for graft injury. In this webinar, you will learn the state-of-the-art understanding of the role of donor-derived cfDNA in post-transplant monitoring of graft injury and its potential clinical utility. We shall review the different technologies available for relative and absolute quantification of dd-cfDNA, and how these technological choices impact laboratory workflow, turnaround time, analytical performance. We discuss how different biofluid sample sources may give different insight into graft injury. We shall introduce HoloGRAFT, Omixon's proprietary cell-free DNA assay and compare its measurement principle with other alternatives. We present the available clinical data to support the performance of the test in kidney transplantation. The session is followed by live Q&A.